Basilea reports strong 2023 full-year results with

Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million...

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Basilea ,Basel Stadt ,Swiss ,Adesh Kaul ,Nils Schr ,David Veitch ,Head Of Corporate Communications Investor Relations ,Biomedical Advanced Research ,Human Services ,Us Department Of Health ,Basilea Pharmaceutica Ltd ,Basilea Pharmaceutica International Ltd ,Development Authority ,Administration For Strategic Preparedness ,Swiss Exchange ,Pharmaceutica Ltd ,Chief Executive Officer ,Chief Financial Officer ,Corporate Communications ,Pharmaceutica International Ltd ,Strategic Preparedness ,Swiss Stock Exchange Bsln ,Basilea Pharmaceutica Ag ,